Ellevest Inc. Has $664,000 Stock Position in Takeda Pharmaceutical Co. $TAK

Ellevest Inc. grew its stake in Takeda Pharmaceutical Co. (NYSE:TAK) by 51.6% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 42,949 shares of the company’s stock after purchasing an additional 14,612 shares during the quarter. Ellevest Inc.’s holdings in Takeda Pharmaceutical were worth $664,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. NewSquare Capital LLC lifted its stake in shares of Takeda Pharmaceutical by 182.4% in the 2nd quarter. NewSquare Capital LLC now owns 3,451 shares of the company’s stock valued at $53,000 after purchasing an additional 2,229 shares during the period. Farther Finance Advisors LLC lifted its stake in shares of Takeda Pharmaceutical by 21.7% in the 2nd quarter. Farther Finance Advisors LLC now owns 5,623 shares of the company’s stock valued at $87,000 after purchasing an additional 1,003 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in shares of Takeda Pharmaceutical in the 1st quarter valued at $125,000. GAMMA Investing LLC increased its position in shares of Takeda Pharmaceutical by 28.6% in the 2nd quarter. GAMMA Investing LLC now owns 9,054 shares of the company’s stock valued at $140,000 after buying an additional 2,012 shares in the last quarter. Finally, Focus Partners Advisor Solutions LLC bought a new stake in shares of Takeda Pharmaceutical in the 2nd quarter valued at $158,000. Institutional investors and hedge funds own 9.17% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on TAK shares. Zacks Research cut shares of Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a research report on Thursday, August 21st. Weiss Ratings restated a “hold (c+)” rating on shares of Takeda Pharmaceutical in a research report on Tuesday, October 14th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold”.

Takeda Pharmaceutical Price Performance

TAK stock opened at $13.59 on Thursday. The stock has a 50-day moving average price of $14.51 and a two-hundred day moving average price of $14.70. The stock has a market cap of $43.24 billion, a PE ratio of 45.30 and a beta of 0.21. The company has a current ratio of 1.16, a quick ratio of 0.59 and a debt-to-equity ratio of 0.60. Takeda Pharmaceutical Co. has a 1 year low of $12.80 and a 1 year high of $15.69.

Takeda Pharmaceutical (NYSE:TAK) last released its earnings results on Thursday, October 30th. The company reported $0.44 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.44. The firm had revenue of $7.32 billion during the quarter, compared to analysts’ expectations of $8.01 billion. Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%. Takeda Pharmaceutical has set its FY 2025 guidance at 3.250-3.250 EPS. Equities analysts forecast that Takeda Pharmaceutical Co. will post 1.64 EPS for the current fiscal year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.